NEUP: Neuphoria Total Debt to Capital

The asset price trajectory on the GURU.Markets platform reflects the price action of Neuphoria Therapeutics Inc. (NEUP), which currently stands at 0.00. The Australian startup is developing unique depression treatments by investing in the study of GABA-A receptors. Patent protection for these molecules limits competitor entry, although FDA oversight and testing risks remain significant. Current capital is stable, enabling the funding of clinical development phases for new drugs.

Maintaining a sustainable financing structure is critical for the biopharmaceutical startup Neuphoria Therapeutics Inc. (NEUP), which is developing findelinele for the treatment of PTSD. This metric is calculated as the ratio of total liabilities to equity, determining the business's reliance on borrowed funds during costly clinical trials. By analyzing the history of the total debt-to-equity ratio, an investor assesses the company's resilience to interest rate shocks and its ability to scale without excessive leverage.